Nagoya Protocol: ‘a masterpiece of ambiguity’

Since the Nagoya Protocol was implemented in October 2014, lawyers, academics, and the life sciences industry broadly have been calling upon institutions such as the European Union for guidance on how to best abide by the new regulations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Pillsbury nabs ‘veteran’ IP litigator and trial lawyer from Goodwin

8 July 2026 After almost 20 years at Goodwin, the patent and trade secrets supremo whose clients include Meta, IBM and Novartis, joins his new employer’s Washington, DC office.

Pharma

Influential Women in IP 2026: Who made the list?

7 July 2026 Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.

Careers

WilmerHale trade secrets expert moves to new firm

7 July 2026 Focusing on technology and life sciences clients, the new San Fran-based Debevoise & Plimpton hire brings both in-house and private practice litigation experience across trade secrets and commercial disputes.

More features

Pillsbury nabs ‘veteran’ IP litigator and trial lawyer from Goodwin

Influential Women in IP 2026: Who made the list?

WilmerHale trade secrets expert moves to new firm

UPC revives patent, but timing sinks Guardant’s appeal

China’s medtech shake-up forces rethink on pricing, IP and innovation

LSD trade secrets suit over clinical trail info thrown out by judge

HGF expands European offering with pair of in-house hires

What’s at stake in Australia’s biggest pharma patent appeal in years?

Nagoya Protocol: ‘a masterpiece of ambiguity’

More on this story

Editor's picks

Editor's picks

More features